In this study, we set out to evaluate the syngeneic NF9006 breast cancer mouse model with the aim to use it for the investigation of anti-CTLA-4-based immunotherapy after low-dose irradiation delivered by application of [177Lu]Lu-DOTA-folate. Here, CTLA4 is linked to breast cancer.